Gout Pipeline Looks Past Uloric To Resistant Patients, Acute Flares

Takeda’s Uloric (febuxostat) ended a forty-year drought for new gout treatments when FDA approved the oral drug for chronic disease on Feb. 13, but a pipeline stocked with new drugs holds the promise of a shorter wait for the next gout therapy.